Cartalax vs TB4-Frag

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.

Active fragment of Thymosin Beta-4; promotes actin dynamics and cell migration; activates hair follicle stem cells; modulates inflammatory signaling

TB-4 Fragment (Thymosin Beta-4 17-23) is a short synthetic peptide derived from the thymosin beta-4 protein, investigated for wound healing, skin repair, and hair follicle regeneration. Thymosin beta-4 facilitates actin sequestration, keratinocyte migration, and stem cell recruitment to sites of tissue injury; the 17-23 fragment retains portions of these bioactive properties. Peer-reviewed studies demonstrate that thymosin beta-4 promotes hair follicle stem cell activation and dermal tissue regeneration in preclinical models, providing a mechanistic basis for skin-related applications. TB-4 Fragment is an investigational peptide with limited human clinical data and is not approved by the FDA for any therapeutic use. TB4-Frag vs full-length thymosin beta-4 TB-4 Fragment (residues 17–23 of thymosin beta-4, sequence: Leu-Lys-Lys-Thr-Glu-Thr-Gln) is a distinct, smaller molecule compared to full-length thymosin beta-4 (43 amino acids). The fragment retains the actin-binding motif that drives keratinocyte migration and stem cell recruitment — mechanisms central to the wound healing and hair follicle regeneration research attributed to TB4 — but lacks the full protein's Ac-SDKP-generating and anti-fibrotic properties. The lower molecular weight of the fragment (approximately 870 Da vs ~4,900 Da for full Tb4) is proposed to improve transdermal penetration for topical applications, making TB4-Frag relevant to cosmetic skin and scalp formulations where injectable administration is not used. In the research peptide market, TB4-Frag is positioned as a topical active for skin repair and hair density contexts; full-length thymosin beta-4 (sold as TB-500) is used for systemic/injectable recovery and tissue repair applications. The two should not be conflated — they have different sequences, molecular weights, and proposed application contexts despite sharing a mechanistic origin.